Список литературы
1. Audeh M. W., Penson R. T., Friedlander M. et.al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009, v.27, p.15s, (suppl; abstr 5500)
2.
Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nature reviews cancer 2009, v.9, p.415-428.3. Burger R. A., Sill M. W., Monk B. J., Greer B. E., and Sorosky J. I.. “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study.” Journal of Clinical Oncology 2007, v. 25, p. 5165–5171,.
4. Burger R. A., Brady M. F., Bookman M. A. et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010, v. 28, p.18s, (suppl; abstr LBA1).
5. Cannistra S. A., Matulonis U. A., Penson R. T., et al. Phase II study of bevacizumab in patients with platinum- resistant ovarian cancer or peritoneal serous cancer.” Journal of Clinical Oncology 2007, v. 25, p. 5180–5186.
6. Kurman R.J., Shin I.-M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008, v.27, p.151-160.
7. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 2008, v,26, p.995-1005.
8. White A. J., Coleman R. L., Armstrong D. K. et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. J Clin Oncol 2010, v. 28, p.15s, (suppl; abstr 5001).
9. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer 2009, v.9, p.167-181.